gabapentin has been researched along with Diffuse Myofascial Pain Syndrome in 35 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This pilot study suggests that OMM treatment and gabapentin are safe and clinically efficacious treatment of pain and other constitutional and somatic symptoms associated with fibromyalgia." | 9.27 | Fibromyalgia with Gabapentin and Osteopathic Manipulative Medicine: A Pilot Study. ( Bernard, N; Bhattacharya, S; Brown, M; Klapstein, G; Marske, C; Palacios, A; Preiss, B; Wheeler, C, 2018) |
| "To assess the efficacy and safety of gabapentin in patients with fibromyalgia." | 9.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "This review replaces part of an earlier review that evaluated gabapentin for both neuropathic pain and fibromyalgia, now split into separate reviews for the two conditions." | 8.95 | Gabapentin for fibromyalgia pain in adults. ( Cooper, TE; Derry, S; Moore, RA; Wiffen, PJ, 2017) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 8.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "The efficacy of gabapentin (GPT) and pregabalin (PGB) in the treatment of fibromyalgia syndrome (FMS) was assessed." | 8.85 | Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. ( Bernardy, K; Häuser, W; Sommer, C; Uçeyler, N, 2009) |
| "We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)." | 7.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| "Fibromyalgia patients had high health care utilization before and after initiation of amitriptyline, duloxetine, gabapentin, or pregabalin." | 7.81 | Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia. ( Kim, SC; Landon, JE; Lee, YC, 2015) |
| "Using US health care utilization data, a large population-based cohort study was conducted to describe clinical characteristics and medication use patterns in patients diagnosed with fibromyalgia who newly started amitriptyline, duloxetine, gabapentin, or pregabalin." | 7.79 | Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. ( Kim, SC; Landon, JE; Solomon, DH, 2013) |
| "This model found pregabalin 300 mg and 450 mg to be cost effective compared with placebo and, within the limits of available evidence, against duloxetine using standard UK criteria in patients with fibromyalgia experiencing severe pain." | 7.76 | Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. ( Bowrin, K; Choy, E; Lloyd, A; Richards, S; Sadosky, A; Watson, P; Zlateva, G, 2010) |
| "The aim of the present study was to determine the brain areas associated with fibromyalgia, and whether pretreatment regional cerebral blood flow (rCBF) can predict response to gabapentin treatment." | 7.76 | Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin. ( Arai, H; Doi, N; Hatta, K; Nakamura, H; Nakanishi, A; Nishioka, K; Usui, C, 2010) |
| "This pilot study suggests that OMM treatment and gabapentin are safe and clinically efficacious treatment of pain and other constitutional and somatic symptoms associated with fibromyalgia." | 5.27 | Fibromyalgia with Gabapentin and Osteopathic Manipulative Medicine: A Pilot Study. ( Bernard, N; Bhattacharya, S; Brown, M; Klapstein, G; Marske, C; Palacios, A; Preiss, B; Wheeler, C, 2018) |
| "To assess the efficacy and safety of gabapentin in patients with fibromyalgia." | 5.12 | Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. ( Arnold, LM; Bishop, F; Goldenberg, DL; Hess, EV; Hudson, JI; Keck, PE; Lalonde, JK; Sandhu, HS; Stanford, KE; Stanford, SB; Welge, JA, 2007) |
| "The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain." | 5.01 | A Clinical Overview of Off-label Use of Gabapentinoid Drugs. ( Brett, AS; Goodman, CW, 2019) |
| "Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "We know from adult randomised controlled trials that some antiepileptics, such as gabapentin and pregabalin, can be effective in certain chronic pain conditions." | 4.95 | Antiepileptic drugs for chronic non-cancer pain in children and adolescents. ( Clinch, J; Cooper, TE; Heathcote, LC; Howard, R; Krane, E; Lord, SM; Schechter, N; Sethna, N; Wiffen, PJ; Wood, C, 2017) |
| "This review replaces part of an earlier review that evaluated gabapentin for both neuropathic pain and fibromyalgia, now split into separate reviews for the two conditions." | 4.95 | Gabapentin for fibromyalgia pain in adults. ( Cooper, TE; Derry, S; Moore, RA; Wiffen, PJ, 2017) |
| "With anticonvulsant, anxiolytic, and analgesic properties, pregabalin has been evaluated for neuropathic pain and fibromyalgia (FM)." | 4.91 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "For gabapentin and pregabalin only we found reasonably good second tier evidence for efficacy in painful diabetic neuropathy and postherpetic neuralgia." | 4.89 | Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. ( Aldington, D; Cole, P; Derry, S; Haanpaa, M; Hamunen, K; Kalso, EA; Lunn, MP; Moore, RA; Rice, AS; Wiffen, PJ, 2013) |
| "This systematic review evaluates the benefits and harms of using the antiepileptic drugs gabapentin and pregabalin for the treatment of fibromyalgia." | 4.87 | Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. ( Cushman, T; Gardner, H; McDonagh, M; Siler, AC; Yanit, K, 2011) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 4.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "The efficacy of gabapentin (GPT) and pregabalin (PGB) in the treatment of fibromyalgia syndrome (FMS) was assessed." | 4.85 | Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. ( Bernardy, K; Häuser, W; Sommer, C; Uçeyler, N, 2009) |
| "We assessed the efficacy and safety of extended-release gabapentin in a 15-week, open-label, single-arm, single-center study in patients with fibromyalgia (FM)." | 3.83 | The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study. ( Hong, KS; North, JM; Rauck, RL, 2016) |
| "Fibromyalgia patients had high health care utilization before and after initiation of amitriptyline, duloxetine, gabapentin, or pregabalin." | 3.81 | Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia. ( Kim, SC; Landon, JE; Lee, YC, 2015) |
| "Using US health care utilization data, a large population-based cohort study was conducted to describe clinical characteristics and medication use patterns in patients diagnosed with fibromyalgia who newly started amitriptyline, duloxetine, gabapentin, or pregabalin." | 3.79 | Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. ( Kim, SC; Landon, JE; Solomon, DH, 2013) |
| "This model found pregabalin 300 mg and 450 mg to be cost effective compared with placebo and, within the limits of available evidence, against duloxetine using standard UK criteria in patients with fibromyalgia experiencing severe pain." | 3.76 | Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. ( Bowrin, K; Choy, E; Lloyd, A; Richards, S; Sadosky, A; Watson, P; Zlateva, G, 2010) |
| "The aim of the present study was to determine the brain areas associated with fibromyalgia, and whether pretreatment regional cerebral blood flow (rCBF) can predict response to gabapentin treatment." | 3.76 | Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin. ( Arai, H; Doi, N; Hatta, K; Nakamura, H; Nakanishi, A; Nishioka, K; Usui, C, 2010) |
| "The data from the fibromyalgia impact questionnaire (FIQ) and the physical and mental subscales short form 36 (SF36) were extracted at last follow-up." | 2.82 | Pharmacological management of fibromyalgia: a Bayesian network meta-analysis. ( Colarossi, G; Eschweiler, J; Knobe, M; Maffulli, N; Migliorini, F; Tingart, M, 2022) |
| "Anxiety and depression are often also present." | 1.35 | Fibromyalgia: poorly understood; treatments are disappointing. ( , 2009) |
| "Vgx rats showed sustained hyperalgesia in the gastrocnemius muscle without tissue damage (no increase in vgx-induced plasma creatine phosphokinase or lactose dehydrogenase levels) accompanied by hypersensitivity to colonic distension." | 1.35 | Subdiaphragmatic vagotomy promotes nociceptive sensitivity of deep tissue in rats. ( Furuta, S; Horie, S; Kuzumaki, N; Matsumoto, K; Narita, M; Shimizu, T; Suzuki, T, 2009) |
| "The surgical treatment of cervical myelopathy due to spinal cord or caudal brainstem compression in patients carrying the diagnosis of fibromyalgia can result in a significant improvement in a wide array of symptoms usually attributed to fibromyalgia with attendant measurable improvements in the quality of life." | 1.34 | Treatment of cervical myelopathy in patients with the fibromyalgia syndrome: outcomes and implications. ( Elias, DA; Heffez, DS; Kostas, K; Morrissey, M; Ross, RE; Shade-Zeldow, Y; Shepard, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 20 (57.14) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Migliorini, F | 1 |
| Maffulli, N | 1 |
| Eschweiler, J | 1 |
| Knobe, M | 1 |
| Tingart, M | 1 |
| Colarossi, G | 1 |
| Merante, D | 1 |
| Dhokia, M | 1 |
| Elander, J | 1 |
| Clements, K | 1 |
| Gilbert, P | 1 |
| Mathieson, S | 1 |
| Lin, CC | 1 |
| Underwood, M | 1 |
| Eldabe, S | 1 |
| Wiffen, PJ | 6 |
| Derry, S | 5 |
| Bell, RF | 1 |
| Rice, AS | 3 |
| Tölle, TR | 1 |
| Phillips, T | 1 |
| Moore, RA | 5 |
| Cooper, TE | 2 |
| Heathcote, LC | 1 |
| Clinch, J | 1 |
| Howard, R | 1 |
| Krane, E | 1 |
| Lord, SM | 1 |
| Sethna, N | 1 |
| Schechter, N | 1 |
| Wood, C | 1 |
| Üçeyler, N | 3 |
| Sommer, C | 3 |
| Walitt, B | 2 |
| Häuser, W | 3 |
| Marske, C | 1 |
| Bernard, N | 1 |
| Palacios, A | 1 |
| Wheeler, C | 1 |
| Preiss, B | 1 |
| Brown, M | 1 |
| Bhattacharya, S | 1 |
| Klapstein, G | 1 |
| King, HH | 1 |
| Goodman, CW | 1 |
| Brett, AS | 1 |
| Kim, SC | 2 |
| Landon, JE | 2 |
| Solomon, DH | 1 |
| Aldington, D | 1 |
| Cole, P | 1 |
| Lunn, MP | 1 |
| Hamunen, K | 1 |
| Haanpaa, M | 1 |
| Kalso, EA | 1 |
| Toelle, T | 1 |
| Parker, L | 1 |
| Huelin, R | 1 |
| Khankhel, Z | 1 |
| Wasiak, R | 1 |
| Mould, J | 1 |
| Montserrat-de la Paz, S | 1 |
| García-Giménez, MD | 1 |
| Ángel-Martín, M | 1 |
| Fernández-Arche, A | 1 |
| Lee, YC | 1 |
| North, JM | 1 |
| Hong, KS | 1 |
| Rauck, RL | 1 |
| Abeles, M | 1 |
| Solitar, BM | 1 |
| Pillinger, MH | 1 |
| Abeles, AM | 1 |
| Bannwarth, B | 1 |
| Nishiyori, M | 1 |
| Ueda, H | 1 |
| Bernardy, K | 1 |
| Peres, MF | 1 |
| Furuta, S | 1 |
| Shimizu, T | 1 |
| Narita, M | 2 |
| Matsumoto, K | 1 |
| Kuzumaki, N | 1 |
| Horie, S | 1 |
| Suzuki, T | 1 |
| Choy, E | 1 |
| Richards, S | 1 |
| Bowrin, K | 1 |
| Watson, P | 1 |
| Lloyd, A | 1 |
| Sadosky, A | 1 |
| Zlateva, G | 1 |
| Usui, C | 1 |
| Hatta, K | 1 |
| Doi, N | 1 |
| Nakanishi, A | 1 |
| Nakamura, H | 1 |
| Nishioka, K | 1 |
| Arai, H | 1 |
| Tzellos, TG | 1 |
| Toulis, KA | 1 |
| Goulis, DG | 1 |
| Papazisis, G | 1 |
| Zampeli, VA | 1 |
| Vakfari, A | 1 |
| Kouvelas, D | 1 |
| Siler, AC | 1 |
| Gardner, H | 1 |
| Yanit, K | 1 |
| Cushman, T | 1 |
| McDonagh, M | 1 |
| McQuay, HJ | 1 |
| Arnold, LM | 1 |
| Goldenberg, DL | 2 |
| Stanford, SB | 1 |
| Lalonde, JK | 1 |
| Sandhu, HS | 1 |
| Keck, PE | 1 |
| Welge, JA | 1 |
| Bishop, F | 1 |
| Stanford, KE | 1 |
| Hess, EV | 1 |
| Hudson, JI | 1 |
| Heffez, DS | 1 |
| Ross, RE | 1 |
| Shade-Zeldow, Y | 1 |
| Kostas, K | 1 |
| Morrissey, M | 1 |
| Elias, DA | 1 |
| Shepard, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Randomized Placebo-Controlled Clinical Trial of Preoperative Gabapentin Prior to Vaginal Apical Suspension Prolapse Procedures[NCT05658887] | Phase 4 | 110 participants (Anticipated) | Interventional | 2023-01-01 | Enrolling by invitation | ||
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Fibromyalgia of Less Than One Year Duration in Primary Care: Treatment Response in a Double Blind, Placebo Controlled Study of Pregabalin[NCT01397006] | Phase 4 | 0 participants (Actual) | Interventional | 2011-09-30 | Withdrawn | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.[NCT02052414] | 34 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia[NCT01107574] | Phase 3 | 41 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients[NCT02406313] | 152 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Fibromyalgia Impact Questionnaire (FIQ) is an instrument designed to quantitate the overall impact of fibromyalgia over many dimensions (e.g. function, pain level, fatigue, sleep disturbance, psychological distress etc.). It is scored from 0 to 100 with the latter number being the worst case. The average score for patients seen in tertiary care settings is about 50. The FIQ is widely used to assess change in fibromyalgia status. (NCT02052414)
Timeframe: 15 weeks.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| FIQ Baseline | FIQ Week 4 | FIQ Week 8 | FIQ Week 12 | FIQ Week 15 | |
| Gralise (Gabapentin ER) | 71.04 | 41.82 | 40.79 | 39.27 | 61.86 |
"Medical Outcomes Study (MOS) sleep questionnaires to assess how Fibromyalgia impacts patients' sleep in various areas.~Specifically, Data reported below measured number of hours subjects spent per night sleeping. MOS sleep questionnaires were assessed at each follow up visits. (visits 1, 2, 3, 4, and 5)." (NCT02052414)
Timeframe: 15 weeks
| Intervention | Hours (Mean) | ||||
|---|---|---|---|---|---|
| Sleep Quantity Baseline | Sleep Quantity week 4 | Sleep quantity week 8 | Sleep quantity week 12 | Sleep quantity week 15 | |
| Gralise (Gabapentin ER) | 5.86 | 7.17 | 6.81 | 7.04 | 6.23 |
Fibromyalgia pain experienced by study subjects will be captured using NPRS at baseline visit, at each follow visits that are scheduled to occur every 4 weeks over 12 weeks of treatment period, and at the end of treatment visit that will occur 3 weeks after treatment period (12 weeks treatment period + 3 weeks = 15 weeks). Any difference in NPRS scores between baseline and any subsequent visits will indicate the magnitude of pain relief as reflected in digital scale of 0-10 (0=no pain, 10=worst pain imaginable). (NCT02052414)
Timeframe: 15 weeks
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| NPRS Baseline (Visit 1) | NPRS on Week 4 (Visit 2) | NPRS on week 8 (Visit 3) | NPRS on Week 12 (Visit 4) | NPRS on week 15 (Visit 5) | |
| Gralise (Gabapentin ER) | 7.29 | 4.72 | 3.95 | 3.83 | 6.94 |
Patient Global impression of Change (PGIC) is an outcome commonly used measure of the efficacy of treatments. PGIC is a 7 point scale that requires the subjects to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT02052414)
Timeframe: 15 Weeks.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PGIC After 4 weeks | PGIC After 8 weeks | PGIC After 12 weeks | PGIC After 15 weeks | |
| Gralise (Gabapentin ER) | 4.96 | 5.40 | 5.37 | 4.44 |
Side / adverse effects were assessed at each follow up visits and resulted are as follows. (NCT02052414)
Timeframe: 15 Weeks
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Extremity Swelling | Weight Gain | Drowsy | Dizzy | Irritability | Dry Eyes | Pain | Mood Changes | Difficulty Concentrating | Dry Mouth | Suspected Drug interaction | Acute Delerium | Adhesion | None | |
| Gralise (Gabapentin ER) | 2 | 2 | 8 | 3 | 3 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 12 |
19 reviews available for gabapentin and Diffuse Myofascial Pain Syndrome
| Article | Year |
|---|---|
Pharmacological management of fibromyalgia: a Bayesian network meta-analysis.
Topics: Analgesics; Duloxetine Hydrochloride; Fibromyalgia; Gabapentin; Humans; Network Meta-Analysis; Prega | 2022 |
The mirogabalin ALDAY phase 3 program in pain associated with fibromyalgia: the lessons learned.
Topics: Bridged Bicyclo Compounds; Clinical Trials, Phase III as Topic; Double-Blind Method; Fibromyalgia; G | 2020 |
Pregabalin and gabapentin for pain.
Topics: Analgesics; Diabetic Neuropathies; Evidence-Based Medicine; Fibromyalgia; Gabapentin; Humans; Neural | 2020 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur | 2017 |
Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Amines; Amitriptyline; Anticonvulsants; Child; Chronic Pain; Complex Regional Pain Syndr | 2017 |
WITHDRAWN: Anticonvulsants for fibromyalgia.
Topics: Acetamides; Amines; Anticonvulsants; Conflict of Interest; Cyclohexanecarboxylic Acids; Fibromyalgia | 2017 |
A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
Topics: Analgesics; Diabetic Neuropathies; Drug Approval; Fibromyalgia; Gabapentin; Humans; Low Back Pain; M | 2019 |
Anticonvulsants for fibromyalgia.
Topics: Acetamides; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric A | 2013 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Fibromyalgia; | 2014 |
A systematic review of pharmacoeconomic studies for pregabalin.
Topics: Amines; Analgesics; Anticonvulsants; Chronic Disease; Cost-Benefit Analysis; Cyclohexanecarboxylic A | 2015 |
Gabapentin for fibromyalgia pain in adults.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Fibromyalgia; Gabapentin; gamma-Amin | 2017 |
Update on fibromyalgia therapy.
Topics: Amines; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents; Complementa | 2008 |
Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials.
Topics: Amines; Analgesics; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Databases, Bibliographic; | 2009 |
Fibromyalgia and headache disorders.
Topics: Amines; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric Acid; Headache Dis | 2009 |
Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis.
Topics: Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Fem | 2010 |
Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia.
Topics: Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabape | 2011 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2011 |
Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain.
Topics: Adrenergic Uptake Inhibitors; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tr | 2007 |
3 trials available for gabapentin and Diffuse Myofascial Pain Syndrome
| Article | Year |
|---|---|
A randomized-controlled pilot trial of an online compassionate mind training intervention to help people with chronic pain avoid analgesic misuse.
Topics: Acetaminophen; Adult; Analgesics; Analgesics, Opioid; Arthritis, Rheumatoid; Aspirin; Back Pain; Chr | 2020 |
Fibromyalgia with Gabapentin and Osteopathic Manipulative Medicine: A Pilot Study.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Fibromyalgia; Gabapentin; gamma-Aminobutyri | 2018 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Double-Blind Meth | 2007 |
13 other studies available for gabapentin and Diffuse Myofascial Pain Syndrome
| Article | Year |
|---|---|
Fibromyalgia Symptoms Reduced by Osteopathic Manipulative Medicine and Gabapentin.
Topics: Fibromyalgia; Gabapentin; Humans; Manipulation, Osteopathic; Osteopathic Medicine; Pilot Projects | 2018 |
Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin.
Topics: Amines; Amitriptyline; Analgesics; Anti-Anxiety Agents; Antidepressive Agents; Cyclohexanecarboxylic | 2013 |
Validation and additional support for an experimental animal model of fibromyalgia.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Dinoprostone; Disease Models, Animal; Female; Fibromya | 2015 |
Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia.
Topics: Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Cohort Studies; Cyclohexanecarboxylic Acids; | 2015 |
The Effect of a Novel form of Extended-Release Gabapentin on Pain and Sleep in Fibromyalgia Subjects: An Open-Label Pilot Study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Prep | 2016 |
Is there a role for anticonvulsants in the management of rheumatic pain?
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2008 |
Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia.
Topics: Amines; Analgesia; Analgesics; Animals; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug Ad | 2008 |
Fibromyalgia: poorly understood; treatments are disappointing.
Topics: Acetaminophen; Acupuncture Therapy; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2009 |
Subdiaphragmatic vagotomy promotes nociceptive sensitivity of deep tissue in rats.
Topics: Amines; Amitriptyline; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Diaphragm; Disease | 2009 |
Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Topics: Adult; Amines; Amitriptyline; Analgesics; Antidepressive Agents; Cost-Benefit Analysis; Cyclohexanec | 2010 |
Brain perfusion in fibromyalgia patients and its differences between responders and poor responders to gabapentin.
Topics: Adult; Aged; Amines; Analgesics; Brain; Cerebrovascular Circulation; Cyclohexanecarboxylic Acids; Cy | 2010 |
Treatment of cervical myelopathy in patients with the fibromyalgia syndrome: outcomes and implications.
Topics: Adult; Amines; Analgesics; Case-Control Studies; Cervical Vertebrae; Cyclohexanecarboxylic Acids; De | 2007 |
Fibromyalgia: understanding a mysterious ailment.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Aminobutyric Acid; | 2007 |